Tianjin Hemay Pharmaceutical
Small-molecule pharma (private)
Privately held: no public share price · China
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | PDE4Small molecule | Inflammatory Bowel DiseasePsoriasis Ulcerative Colitis | |
Hemay007No recent activity | Phase 1 | TNF-alphaSmall molecule | Inflammatory Bowel Disease Crohn's Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.